In a high-stakes move to consolidate its position in the obesity drug market Novo Nordisks CEO Mike Doustdar made an unexpected 10 billion bid for Metsera Despite knowing that Metsera had already accepted a 73 billion bid from Pfizer Doustdar was determined not to let go of the promising company as revealed by US securities filings and court documents
